Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Conclusion
Over one-third of Korean adults have MASLD/related SLD and bear a high CVD risk. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Lee, H.-H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., Kim, S. U. Tags: Gut Hepatology Source Type: research
Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis
Conclusion
Lower serum TC can causally increase the risk of cholelithiasis. The cholelithiasis risk would increase with the elevation of serum TG but would decrease when exceeding 2.57 mmol/L. The use of HMGCR inhibitors should prevent its risk. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Chen, L., Qiu, W., Sun, X., Gao, M., Zhao, Y., Li, M., Fan, Z., Lv, G. Tags: Gut Hepatology Source Type: research
Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy
Conclusion
We propose that CD29+ Tregs constitute a unique subpopulation of hepatic Tregs that are primed to respond to ICI agents and mediate resistance. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Green, B. L., Myojin, Y., Ma, C., Ruf, B., Ma, L., Zhang, Q., Rosato, U., Qi, J., Revsine, M., Wabitsch, S., Bauer, K., Benmebarek, M.-R., McCallen, J., Nur, A., Wang, X., Sehra, V., Gupta, R., Claassen, M., Wang, X. W., Korangy, F., Greten, T. F. Tags: Gut Hepatology Source Type: research
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy
Conclusions
The RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: O'Rourke, C. J., Salati, M., Rae, C., Carpino, G., Leslie, H., Pea, A., Prete, M. G., Bonetti, L. R., Amato, F., Montal, R., Upstill-Goddard, R., Nixon, C., Sanchon-Sanchez, P., Kunderfranco, P., Sia, D., Gaudio, E., Overi, D., Cascinu, S., Hogdall, D., P Tags: Open access, Gut Hepatology Source Type: research
Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis
Conclusions
The orointestinal microbiome predicts clinical hallmark features of AP, and SCFAs may be used for future diagnostic and therapeutic concepts.
Trial registration number
NCT04777812. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Ammer-Herrmenau, C., Antweiler, K. L., Asendorf, T., Beyer, G., Buchholz, S. M., Cameron, S., Capurso, G., Damm, M., Dang, L., Frost, F., Gomes, A., Hamm, J., Henker, R., Hoffmeister, A., Meinhardt, C., Nawacki, L., Nunes, V., Panyko, A., Pardo, C., Phill Tags: Open access, Gut Pancreas Source Type: research
Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis
Conclusion
We uncover a mechanism for organ-specific CRC metastasis. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Li, R., Liu, X., Huang, X., Zhang, D., Chen, Z., Zhang, J., Bai, R., Zhang, S., Zhao, H., Xu, Z., Zeng, L., Zhuang, L., Wen, S., Wu, S., Li, M., Zuo, Z., Lin, J., Lin, D., Zheng, J. Tags: Open access, Gut Colon Source Type: research
Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial
Conclusions
Our study shows that ebastine is superior to placebo and should be further evaluated as novel treatment for patients with non-constipated IBS.
Trial registration number
The study protocol was approved by the local ethics committee of each study site (EudraCT number: 2013-001199-39; ClinicalTrials.gov identifier: NCT01908465). (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Decraecker, L., De Looze, D., Hirsch, D. P., De Schepper, H., Arts, J., Caenepeel, P., Bredenoord, A. J., Kolkman, J., Bellens, K., Van Beek, K., Pia, F., Peetermans, W., Vanuytsel, T., Denadai-Souza, A., Belmans, A., Boeckxstaens, G. Tags: Gut Irritable bowel syndrome Source Type: research
Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohns disease
Conclusion
Distinct gut bacterial IgG2-coating was demonstrated in patients with severe CD and during disease flares. Co-occurrence of non-coated pathobionts with IgG2-coated bacteria points to an uncontrolled inflammatory condition in severe CD mediated via escape from antibody coating by two gut pathobionts. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Eriksen, C., Danneskiold-Samsoe, N. B., Moll, J. M., Myers, P. N., Bondegaard, P. W., Vejrum, S., Hansen, T. B., Rosholm, L. B., Rausch, P., Allin, K. H., Jess, T., Kristiansen, K., Penders, J., Jonkers, D., Brix, S. Tags: Gut Inflammatory bowel disease Source Type: research
Reducing scope 3 carbon emissions in gastrointestinal endoscopy: results of the prospective study of the 'Green Endoscopy Project Würzburg
Conclusion
Use of fewer instruments per procedure, recycling packaging material and switching to alternative products can reduce carbon emissions without impairing the endoscopic workflow. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Henniger, D., Lux, T., Windsheimer, M., Brand, M., Weich, A., Kudlich, T., Schöttker, K., Hann, A., Meining, A. Tags: Open access, Gut Endoscopy Source Type: research
Colonic spider naevi in a middle-aged man
Introduction A 59-year-old man was seen in outpatient clinic with a 1-year history of abdominal cramping and non-bloody diarrhoea. His only medical history comprised hypercholesterolaemia and oesophagogastric reflux, for which he took simvastatin and lansoprazole. He did not show cutaneous spider naevi and there was no history of liver disease or use of oestrogen or hormone replacement medications. CT of the abdomen and pelvis showed a long segment of moderate sigmoid colonic wall thickening (figure 1A) with perifocal fat stranding and free fluid in keeping with acute sigmoiditis. Feeding vessels were patent with no eviden...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Hunter, H., Johnston, A. J., Said, W., Wong, N. A. Tags: GUT Snapshot, Gut Editor ' s quiz: GI snapshot Source Type: research
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates
At the end of the last century, a far-sighted ‘working party’ held in Sydney, Australia addressed the clinicopathological issues related to gastric inflammatory diseases. A few years later, an international conference held in Houston, Texas, USA critically updated the seminal Sydney classification. In line with these initiatives, Kyoto Global Consensus Report, flanked by the Maastricht-Florence conferences, added new clinical evidence to the gastritis clinicopathological puzzle.
The most relevant topics related to the gastric inflammatory diseases have been addressed by the Real-world Gastritis Initiative (RE.G...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Rugge, M., Genta, R. M., Malfertheiner, P., Dinis-Ribeiro, M., El-Serag, H., Graham, D. Y., Kuipers, E. J., Leung, W. K., Park, J. Y., Rokkas, T., Schulz, C., El-Omar, E. M., RE.GA.IN, RE GA IN, Bordin, Constanza Camargo, Coelho, Mario, Sabatino, Dumitras Tags: Editor's choice, Gut Stomach Source Type: research
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study
Conclusion
Dupilumab 300 mg once a week demonstrated efficacy and was well tolerated in patients with EoE regardless of prior STC use or inadequate response, intolerance and/or contraindication to STC.
Trial registration number
NCT03633617. (Source: Gut)
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Bredenoord, A. J., Dellon, E. S., Hirano, I., Lucendo, A. J., Schlag, C., Sun, X., Glotfelty, L., Mannent, L., Maloney, J., Laws, E., Mortensen, E., Shabbir, A. Tags: Open access, Gut Oesophagus Source Type: research
EUS-guided gallbladder drainage in acute cholecystitis: long-term problems with surgical approach
Message Professional societies have endorsed endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) as an alternative to percutaneous cholecystostomy in high-risk surgical patients with acute cholecystitis. In a retrospective case series, we encountered 3 of 25 patients who improved clinically after EUS-GBD and subsequently had their surgical risk status reversed when cholecystectomy was indicated due to persistent symptoms. However, the presence of a lumen-apposing metal stent (LAMS) precluded a minimally invasive surgical approach and necessitated conversion to open or subtotal cholecystectomy. Therefore, EUS-GBD sh...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Bang, J. Y., Arnoletti, J. P., Wagner, A., Varadarajulu, S. Tags: Open access, Gut Endoscopy news Source Type: research
Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?
There is increasing evidence that the pathophysiology of irritable bowel syndrome (IBS), once considered a functional gastrointestinal disorder and now reframed as a disorder of gut–brain interaction,1 has an organic basis. Some patients with IBS exhibit evidence of low-grade mucosal inflammation.2 One of the most well-replicated observations over the last 20 years has been reports of mast cell activation in IBS, with degranulation and a resulting increase in mucosal tryptase and histamine,3 as well as increased proximity of mast cells to visceral nerves, which correlate with abdominal pain severity and frequency. Co...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Ford, A. C. Tags: Gut Commentary Source Type: research
Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism
During the past few decades, the field of immuno-oncology has evolved along with the development of novel immunotherapies targeting Foxp3-expressing regulatory T cells (Tregs), a distinctive lineage of CD4+ T cells, for patients with cancer. There is considerable experimental and clinical evidence to support the role of Tregs in tumour growth, progression and metastasis, thus favouring suppression of antitumor immune responses and, therefore, immune escape.1 However, its role in cancer is somehow controversial and continues to be studied in order to enlarge the few therapeutic options currently available for patients with ...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Cubero, F. J., Sarobe, P., Tiegs, G. Tags: Gut Commentary Source Type: research
